• VIDEO: Antibody-drug conjugate ‘encouraging' in lung cancer subsets

    1 month ago - By Healio

    In an interview with Healio, Pasi A. Jänne, MD, PhD, discussed a study on the use of an antibody-drug conjugate in some patients with non-small cell lung cancer.
    Jänne, director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and professor of medicine at Harvard Medical School, explained that phase 1 trial results presented at the meeting from a study assessing the TROP2 antibody-drug conjugate DS-1062a found that there was some response to treatment among patients with advanced or metastatic NSCLC who had actionable genomic
    Read more ...

     

  • FDA approves Tecentriq for new lung cancer indication

    FDA approves Tecentriq for new lung cancer indication

    1 month ago - By Healio

    The FDA expanded the approval of atezolizumab to include adjuvant treatment of certain patients with non-small cell lung cancer.
    The approval applies to use of the agent after resection and platinum-based chemotherapy for patients with stage II to stage IIIA NSCLC whose tumors have PD-L1 expression on at least 1% of tumor cells.
    Atezolizumab , an anti-PD-L1 monoclonal antibody, is approved in the United States for multiple lung cancer indications. It also is approved for treatment of certain patients with melanoma, hepatocellular carcinoma and urothelial carcinoma.
    Read more ...

     

  • First Adjuvant Immunotherapy OK'd in Non-Small Cell Lung Cancer

    First Adjuvant Immunotherapy OK'd in Non-Small Cell Lung Cancer

    1 month ago - By MedPageToday

    The FDA approved the PD-L1 inhibitor atezolizumab as adjuvant treatment following surgery and platinum-based chemotherapy for stage II-IIIa non-small cell lung cancer that expresses PD-L1.
    The new approval...
    Read more ...

     

  • FDA OKs Adjuvant Atezolizumab for Early-Stage Lung Cancer

    FDA OKs Adjuvant Atezolizumab for Early-Stage Lung Cancer

    1 month ago - By Medscape

    The drug is now also approved for adjuvant treatment following resection and platinum-based chemotherapy in early stage, non-small cell lung cancer with PD-L1 ≥ 1%.
    FDA Approvals
    Read more ...